#radioimmunoassay | Explore Tumblr Posts and Blogs

proverbiumseniorum · 2 years

Text

"The excitement of learning separates youth from old age. As long as you are learning you're not old."---Rosalyn Sussman Yalow, U.S. Nobel laureate medical physicist, 1921-2011

“The excitement of learning separates youth from old age. As long as you are learning you’re not old.”—Rosalyn Sussman Yalow, U.S. Nobel laureate medical physicist, 1921-2011

View On WordPress

#radioimmunoassay #RIA #Rosalyn Sussman Yalow #U.S. Nobel laureate medical physicist

0 notes

nidarsanafwr · 6 months

Text

https://joyrulez.com/blogs/421359/Radio-Immunoassay-RIA-Reagents-and-Devices-Market-Size-Analysis-and

Radio Immunoassay (RIA) Reagents and Devices Market Size, Analysis and Forecast 2031

#RadioImmunoassay(RIA)ReagentsandDevicesMarket #RadioImmunoassay(RIA)ReagentsandDevicesMarketSize #RadioImmunoassay(RIA)ReagentsandDevicesMarketShare #RadioImmunoassay(RIA)ReagentsandDevicesMarketScope

0 notes

science-sculpt · 7 months

Text

ELISA: A Powerful Tool for Detecting the Invisible

ELISA, or Enzyme-Linked Immunosorbent Assay, has become a cornerstone of medical diagnostics and biological research. This versatile technique allows scientists to detect and quantify minute amounts of target molecules, such as proteins, antibodies, and even viruses, with remarkable accuracy. In this blog, we'll delve into the world of ELISA, exploring its various types, its applications, and the exciting future directions this technology holds.

At its core, ELISA relies on the exquisite specificity of antibodies. Antibodies are highly specialized proteins produced by the immune system in response to foreign invaders. Each antibody can bind to a unique structure, called an antigen, on a specific molecule. In an ELISA, scientists leverage this binding property to create a sensitive detection system.

The 1960s witnessed a surge in interest in immunoassays, techniques that utilize the specificity of antibodies to detect target molecules. One such technique, radioimmunoassay (RIA), developed by Rosalyn Yalow and Solomon Berson, revolutionized medical diagnostics. RIA used radioactively labeled antibodies to detect antigens, offering high sensitivity. However, concerns regarding the safety of radioactive materials fueled the search for a safer alternative. The year 1971 marked a turning point. Independently, Eva Engvall and Peter Perlmann published their work on a novel technique – the enzyme-linked immunosorbent assay (ELISA). ELISA replaced radioactive labels with enzymes, eliminating the safety concerns associated with RIA. Like RIA, ELISA harnessed the specific binding between antibodies and antigens. However, it employed enzymes that could generate a detectable signal, such as a color change, upon interacting with a substrate. This innovation paved the way for a safer and more user-friendly diagnostic tool.

The basic ELISA protocol involves immobilizing the target antigen on a solid surface like a plate well. Then, a sample containing the molecule of interest (e.g., a suspected virus) is introduced. If the target molecule is present, it will bind to the immobilized antigen. Next, an antibody specific to the target molecule, linked to an enzyme, is introduced. This "detection antibody" binds to the target molecule already attached to the antigen. Finally, a substrate specific to the enzyme is added. This antigen-antibody binding is visualized using an enzyme linked to a reporter molecule. When the enzyme encounters its substrate, a detectable signal is produced, such as a color change or luminescence. The intensity of this signal is directly proportional to the amount of antigen present in the sample, allowing for quantification. The beauty of ELISA lies in its adaptability. Several variations exist, each tailored for specific detection needs.

The Four Main ELISA Formats are:

Direct ELISA: Simplicity at its finest. In this format, the antigen is directly coated onto the ELISA plate. A labeled antibody specific to the antigen is then introduced, binding directly to its target. After washing away unbound molecules, the enzyme linked to the antibody generates a signal upon addition of the substrate. Direct ELISA offers a rapid and straightforward approach, but sensitivity can be lower compared to other formats due to the lack of amplification.

Indirect ELISA: Unveiling the Power of Amplification. Similar to the direct ELISA, the antigen is first coated onto the plate. However, instead of a labeled primary antibody, an unlabeled one specific to the antigen is used. This is followed by the introduction of a labeled secondary antibody that recognizes the species (e.g., mouse, rabbit) of the primary antibody. This two-step approach acts as an amplification strategy, significantly enhancing the signal compared to the direct ELISA. However, the presence of an extra incubation step and the potential for cross-reactivity with the secondary antibody add complexity.

Sandwich ELISA: Capturing the Antigen Between Two Antibodies. Here, the capture antibody, specific for one region of the antigen, is pre-coated onto the ELISA plate. The sample containing the antigen is then introduced, allowing it to be "sandwiched" between the capture antibody and a detection antibody specific for a different region of the same antigen. A labeled secondary antibody or a labeled detection antibody itself can then be used to generate the signal. Sandwich ELISA boasts high sensitivity due to the double-antibody recognition and is often the preferred format for quantifying analytes.

Competitive ELISA: A Race for Binding Sites. In this format, the antigen competes with a labeled antigen (usually a known amount) for binding sites on a capture antibody pre-coated onto the plate. The more antigen present in the sample, the less labeled antigen can bind to the capture antibody. Following a washing step, the amount of bound labeled antigen is measured, providing an inverse relationship between the signal and the concentration of antigen in the sample. Competitive ELISA is particularly useful for studying small molecules that may be difficult to directly conjugate to an enzyme.

ELISA's Reach: From Diagnostics to Research. The applications of ELISA are as vast as they are impressive. Let's delve into some key areas where ELISA plays a vital role:

Unveiling the Mysteries of Disease: Diagnostics: ELISA is a cornerstone of diagnosing infectious diseases like HIV, Hepatitis, and Lyme disease. It detects antibodies produced by the body in response to the invading pathogen, providing valuable information for early detection and treatment. Monitoring Autoimmune Diseases: ELISA helps monitor autoimmune diseases like rheumatoid arthritis and lupus by measuring specific antibodies associated with these conditions. Cancer Screening: Certain cancers can be detected by identifying tumor markers, proteins elevated in the blood of cancer patients. ELISA assays are being developed to detect these markers for early cancer screening.

Safeguarding Food Quality: Allergen Detection: Food allergies can be life-threatening. ELISA ensures food safety by enabling the detection of allergens like peanuts, gluten, and milk in food products, protecting consumers with allergies. Monitoring Foodborne Pathogens: ELISA can identify harmful bacteria, viruses, and toxins in food, preventing outbreaks of foodborne illnesses.

Environmental Monitoring: Pollutant Detection: ELISA can detect pollutants like pesticides and herbicides in water and soil samples, contributing to environmental protection efforts. Microbial Analysis: This technique can be used to identify and quantify specific microbes in environmental samples, providing insights into ecosystem health.

Research and Development: ELISA plays a crucial role in various research fields: Drug Discovery: It helps researchers assess the effectiveness of new drugs by measuring drug-target interactions and monitoring drug levels in the body. Vaccine Development: ELISA is instrumental in developing vaccines by evaluating immune responses to vaccine candidates. Basic Research: Scientists use ELISA to study various biological processes by detecting and quantifying specific molecules involved in these processes.

Despite its established role, ELISA is evolving alongside technological advancements. New multiplex platforms allow for the simultaneous detection of various targets in a single sample, boosting efficiency in biomarker discovery and disease analysis. Automation streamlines workflows minimizes errors, and increases throughput, making high-throughput screening feasible in drug development and clinical settings. Miniaturization and portable devices enable rapid on-site diagnostics, providing healthcare professionals with real-time data for quicker interventions. Additionally, ongoing research is improving assay sensitivity, reducing background noise, and expanding detection limits, allowing for the identification of trace analytes and early disease biomarkers with greater accuracy than ever before. Integration of ELISA with emerging technologies such as microfluidics, nanotechnology, and artificial intelligence holds promise for enhancing assay performance, scalability, and data analysis capabilities.

These advancements hold promise for even wider applications of ELISA in the future. ELISA has revolutionized our ability to detect and quantify biological molecules. Its versatility, accuracy, and adaptability make it an invaluable tool across various scientific disciplines. As research continues to refine and innovate ELISA techniques, we can expect even more exciting possibilities to emerge in the years to come. ELISA's future is bright, promising to play a pivotal role in unraveling the mysteries of the biological world and improving human health.

11 notes · View notes

girlactionfigure · 2 years

Text

Immense pride, tinged with sadness.

For those who would like to read the full list:

1908 MECHNIKOV, ELIE

FOR THEIR WORK ON IMMUNITY

1908 EHRLICH, PAUL

FOR THEIR WORK ON IMMUNITY

1914 BARANY, ROBERT

FOR HIS WORK ON THE PHYSIOLOGY AND PATHOLOGY OF THE VESTIBULAR APPARATUS

1922 MEYERHOF, OTTO FRITZ

FOR HIS DISCOVERY OF THE FIXED RELATIONSHIP BETWEEN THE CONSUMPTION OF

OXYGEN AND THE METABOLISM OF LACTIC ACID IN THE MUSCLE

1930 LANDSTEINER, KARL

FOR HIS DISCOVERY OF HUMAN BLOOD GROUPS

1936 LOEWI, OTTO

FOR THEIR DISCOVERIES RELATING TO CHEMICAL TRANSMISSION OF NERVE IMPULSES

1944 ERLANGER, JOSEPH

FOR THEIR DISCOVERIES RELATING TO THE HIGHLY DIFFERENTIATED FUNCTIONS OF SINGLE NERVE FIBRES

1945 CHAIN, ERNST BORIS

FOR THE DISCOVERY OF PENICILLIN AND ITS CURATIVE EFFECT IN VARIOUS INFECTIOUS DISEASES

1946 MULLER, HERMANN J.

FOR THE DISCOVERY OF THE PRODUCTION OF MUTATIONS BY MEANS OF X-RAY IRRADIATION

1947 CORI, GERTY THERESA, RADNITZ

FOR THEIR DISCOVERY OF THE COURSE OF THE CATALYTIC CONVERSION OF GLYCOGEN

1950 REICHSTEIN, TADEUS

FOR THEIR DISCOVERIES RELATING TO THE HORMONES OF THE ADRENAL CORTEX, THEIR STRUCTURE AND BIOLOGICAL EFFECTS

1952 WAKSMAN, SELMAN A.

FOR HIS DISCOVERY OF STREPTOMYCIN, THE FIRST ANTIBIOTIC EFFECTIVE AGAINST TUBERCULOSIS

1953 LIPMANN, FRITZ ALBERT

FOR HIS DISCOVERY OF CO-ENZYME A AND ITS IMPORTANCE FOR INTERMEDIARY METABOLISM

1953 KREBS, HANS ADOLF

FOR HIS DISCOVERY OF THE CITRIC ACID CYCLE

1958 LEDERBERG, JOSHUA

FOR HIS DISCOVERIES CONCERNING GENETIC RECOMBINATION AND THE ORGANISATION OF THE GENETIC MATERIAL OF BACTERIA

1959 KORNBERG, ARTHUR

FOR THEIR DISCOVERY OF THE MECHANISMS IN THE BIOLOGICAL SYNTHESIS OF RIBONUCLEIC ACID AND DEOXYRIBONUCLEIC ACID

1964 BLOCH, KONRAD

FOR THEIR DISCOVERIES CONCERNING THE MECHANISM AND REGULATION OF THE CHOLESTEROL AND FATTY ACID METABOLISM

1965 JACOB, FRANCOIS

FOR THEIR DISCOVERIES CONCERNING GENETIC CONTROL OF ENZYME AND VIRUS SYNTHESIS

1965 LWOFF, ANDRE

FOR THEIR DISCOVERIES CONCERNING GENETIC CONTROL OF ENZYME AND VIRUS SYNTHESIS

1967 WALD, GEORGE

FOR THEIR DISCOVERIES CONCERNING THE PRIMARY PHYSIOLOGICAL AND CHEMICAL VISUAL PROCESSES IN THE EYE

1968 NIRENBERG, MARSHALL W.

FOR THEIR INTERPRETATION OF THE GENETIC CODE AND ITS FUNCTION IN PROTEIN SYNTHESIS

1969 LURIA, SALVADOR E.

FOR THEIR DISCOVERIES CONCERNING THE REPLICATION MECHANISM AND THE GENETIC STRUCTURE OF VIRUSES

1970 KATZ, BERNARD

FOR THEIR DISCOVERIES CONCERNING THE HUMORAL TRANSMITTERS IN THE NERVE TERMINALS AND THE MECHANISM

FOR THEIR STORAGE, RELEASE AND INACTIVATION

1970 AXELROD, JULIUS

FOR THEIR DISCOVERIES CONCERNING THE HUMORAL TRANSMITTERS IN THE NERVE TERMINALS AND THE MECHANISM

FOR THEIR STORAGE, RELEASE AND INACTIVATION

1972 EDELMAN, GERALD M.

FOR THEIR DISCOVERIES CONCERNING THE CHEMICAL STRUCTURE OF ANTIBODIES

1975 TEMIN, HOWARD M.

FOR THEIR DISCOVERIES CONCERNING THE INTERACTION BETWEEN TUMOR VIRUSES AND THE GENETIC MATERIAL OF THE CELL

1975 BALTIMORE, DAVID

FOR THEIR DISCOVERIES CONCERNING THE INTERACTION BETWEEN TUMOR VIRUSES AND THE GENETIC MATERIAL OF THE CELL

1976 BLUMBERG, BARUCH S.��

FOR THEIR DISCOVERIES CONCERNING NEW MECHANISMS FOR THE ORIGIN AND DISSEMINATION OF INFECTIOUS DISEASES

1977 YALOW, ROSALYN

FOR THE DEVELOPMENT OF RADIOIMMUNOASSAYS OF PEPTIDE HORMONES

1977 SCHALLY, ANDREW V.

FOR THEIR DISCOVERIES CONCERNING THE PEPTIDE HORMONE PRODUCTION OF THE BRAIN

1978 NATHANS, DANIEL

FOR THE DISCOVERY OF RESTRICTION ENZYMES AND THEIR APPLICATION TO PROBLEMS OF MOLECULAR GENETICS

1980 BENACERRAF, BARUJ

FOR THEIR DISCOVERIES CONCERNING GENETICALLY DETERMINED STRUCTURES ON THE CELL SURFACE THAT

REGULATE IMMUNOLOGICAL REACTIONS

1984 MILSTEIN, CESAR

FOR THEORIES CONCERNING THE SPECIFICITY IN DEVELOPMENT AND CONTROL OF THE IMMUNE SYSTEM AND THE DISCOVERY OF THE

PRINCIPLE FOR PRODUCTION OF MONOCLONAL ANTIBODIES

1985 BROWN, MICHAEL S.

FOR THEIR DISCOVERIES CONCERNING THE REGULATION OF CHOLESTEROL METABOLISM

1985 GOLDSTEIN, JOSEPH L.

FOR THEIR DISCOVERIES CONCERNING THE REGULATION OF CHOLESTEROL METABOLISM

1986 COHEN, STANLEY

FOR THEIR DISCOVERIES OF GROWTH FACTORS

1986 LEVI-MONTALCINI, RITA

FOR THEIR DISCOVERIES OF GROWTH FACTORS

1988 ELION, GERTRUDE B.

FOR THEIR DISCOVERIES OF IMPORTANT PRINCIPLES FOR DRUG TREATMENT

1989 VARMUS, HAROLD E.

FOR THEIR DISCOVERY OF THE CELLULAR ORIGIN OF RETROVIRAL ONCOGENES

1994 RODBELL, MARTIN

FOR THEIR DISCOVERY OF G-PROTEINS AND THE ROLE OF THESE PROTEINS IN SIGNAL TRANSDUCTION IN CELLS

1994 GILMAN, ALFRED G.

FOR THEIR DISCOVERY OF G-PROTEINS AND THE ROLE OF THESE PROTEINS IN SIGNAL TRANSDUCTION IN CELLS

1997 PRUSINER, STANLEY B.

FOR HIS DISCOVERY OF PRIONS - A NEW BIOLOGICAL PRINCIPLE OF INFECTION

1998 FURCHGOTT, ROBERT F.

FOR THEIR DISCOVERIES CONCERNING NITRIC OXIDE AS A SIGNALING MOLECULE IN THE CARDIOVASCULAR SYSTEM

2000 GREENGARD, PAUL

FOR THEIR DISCOVERIES CONCERNING SIGNAL TRANSDUCTION IN THE NERVOUS SYSTEM

2000 KANDEL, ERIC R.

FOR THEIR DISCOVERIES CONCERNING SIGNAL TRANSDUCTION IN THE NERVOUS SYSTEM

2002 BRENNER, SYDNEY

FOR THEIR DISCOVERIES CONCERNING GENETIC REGULATION OF ORGAN DEVELOPMENT AND PROGRAMMED CELL DEATH

2002 HORVITZ, H. ROBERT

FOR THEIR DISCOVERIES CONCERNING GENETIC REGULATION OF ORGAN DEVELOPMENT AND PROGRAMMED CELL DEATH

2004 AXEL, RICHARD

FOR THEIR DISCOVERIES OF ODORANT RECEPTORS AND THE ORGANIZATION OF THE OLFACTORY SYSTEM

2006 FIRE, ANDREW Z.

FOR THEIR DISCOVERY OF RNA INTERFERENCE - GENE SILENCING BY DOUBLE-STRANDED RNA

2011 STEINMAN, RALPH M.

FOR THEIR DISCOVERIES CONCERNING THE ACTIVATION OF INNATE IMMUNITY

2011 BEUTLER, BRUCE A.

FOR THEIR DISCOVERIES CONCERNING THE ACTIVATION OF INNATE IMMUNITY

2013 SCHEKMAN, RANDY W.

FOR THEIR DISCOVERIES OF MACHINERY REGULATING VESICLE TRAFFIC, A MAJOR TRANSPORT SYSTEM IN OUR CELLS

2013 ROTHMAN, JAMES E.

FOR THEIR DISCOVERIES OF MACHINERY REGULATING VESICLE TRAFFIC, A MAJOR TRANSPORT SYSTEM IN OUR CELLS

2017 ROSBASH, MICHAEL

FOR THEIR DISCOVERIES OF MOLECULAR MECHANISMS CONTROLLING THE CIRCADIAN RHYTHM

Likud Herut UK

#Israel #Nobel prize #Jewish Pride

81 notes · View notes

avconsumables · 2 months

Text

Avconsumbles RIA Vials: Trusted Solutions for Reliable Testing

Discover the excellence of Avconsumbles RIA Vials—your trusted solution for precise and reliable testing. Our vials are expertly designed to meet the highest standards of quality, ensuring accurate results for your radioimmunoassay procedures. With Avconsumbles, you can count on exceptional performance and consistency in every test, helping you achieve dependable outcomes in your research and diagnostics. Explore our range of RIA vials today and experience the difference of premium-grade lab equipment.

#riavial

0 notes

healthcaremarketanalysis · 2 months

Text

Global Therapeutic Drug Monitoring Market worth $2.9 billion by 2027

Therapeutic Drug Monitoring Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by the Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis. However, Alternatives to conventional TDM may challenge the growth of this market.

Download PDF Brochure:

Browse in-depth TOC on "Antiepileptic Drug Monitoring Industry"

178 - Tables

50 - Figures

221 – Pages

Germany in European Antibiotic Therapeutic drug monitoring market to witness the highest shares during the forecast period.

The Europe Therapeutic Drug Monitoring Market is segmented into Germany, Italy, France, Spain, the UK, and the Rest of Europe. Germany is projected to occupy the highest share during the forecast period. The major factors contributing to the growth of this market are the rising geriatric population, increasing incidence of chronic and infectious diseases, rising healthcare expenditure, and increasing R&D investments.

Japan dominates the Asia Pacific Immunosuppressant Drug Monitoring industry

The APAC Therapeutic Drug Monitoring market is segmented into Japan, China, and India. In 2021, Japan accounted for the largest share of the Asian Therapeutic Drug Monitoring market. The large share of Japan can be attributed to the large geriatric population in the country, the rising prevalence of chronic medical conditions such as cancer, growing budgetary allocations for healthcare, and the presence of a well-developed healthcare system.

chemiluminescence immunoassays (CLIAs) in the product's immunoassay therapeutic drug monitoring segment to witness the highest growth as well as the largest share in the therapeutic drug monitoring market during the forecast period.

The market is divided into chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, and other immunoassays based on the immunoassay. The chemiluminescence immunoassays segment is projected to grow at the highest CAGR during the forecast period because these assays are commonly used in TDM in either enzyme-amplified or direct chemiluminescence measurements.

Request 10% Customization:

Antiarrhythmic Drug Monitoring Industry Dynamics:

Drivers:

Importance of TDM in organ transplant procedures

Use of TDM across various therapeutic fields

Increasing preference for precision medicine

Growing focus on R&D related to TDM

Technological advancements

Restraints:

Requirement of high capital investments

Reluctance of small hospitals to offer TDM services

Opportunities:

Increasing adoption in the treatment of autoimmune diseases

Challenges:

Alternatives to conventional TDM

Operational barriers faced in conducting TDM

Key Market Players:

The significant players in the Therapeutic Drug Monitoring industry are Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany), ARK Diagnostics, Inc. (US), apDia Group (Belgium), Immundiagnostik AG (Germany), and Sekisui Medical Co. Ltd. (Japan).

Recent Developments:

In May 22, Theradiag (France) Announced the launch of ez-Track1, a Point-of-Care Testing solution for TDM.

In Jan 2021, Theradiag (France) Announced CE marking for four new i-Tracker test kits for biotherapy monitoring.

Report Objectives

To define, describe, and forecast the global Therapeutic Drug Monitoring market based on product, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)

To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW)2

To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3

To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Therapeutic Drug Monitoring market

Frequently Asked Questions (FAQ):

What is the projected market value of the global Therapeutic Drug Monitoring Market?

The global market of Therapeutic Drug Monitoring is projected to reach USD 2.9 billion by 2027.

What is the estimated growth rate (CAGR) of the global Therapeutic Drug Monitoring Market for the next five years?

The global Therapeutic Drug Monitoring market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.6% from 2022 to 2027.

Who are the major players offering Therapeutic Drug Monitoring in the market?

Abbott (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories (US), bioMérieux SA (France), Theradiag SA (France), Grifols S.A. (Spain), Exagen Inc. (US), R-Biopharm AG (Germany)

Who are the significant end users in Therapeutic Drug Monitoring Market?

Hospital laboratories, commercial & private laboratories, are the major end users in Therapeutic Drug Monitoring Market.

Which Immunoassay will have the highest shares in Therapeutic Drug Monitoring Market during the forecast period?

Chemiluminescence Immunoassays will have the highest shares of the Therapeutic Drug Monitoring market during the forecast period

Report Link: ( Therapeutic Drug Monitoring Market )

#Therapeutic Drug Monitoring Market #Therapeutic Drug Monitoring Industry #Therapeutic Drug Monitoring Market Demand

0 notes

valkyries-things · 2 months

Text

DR. ROSALYN SUSSMAN YALOW // PHYSICIST

“She was an American medical physicist, and a co-winner of the 1977 Nobel Prize in Physiology or Medicine (together with Roger Guillemin and Andrew Schally) for development of the radioimmunoassay technique. She was the second woman (after Gerty Cori), and the first American-born woman, to be awarded the Nobel Prize in Physiology or Medicine.”

#female history #american history #women in stem

0 notes

bhushans · 4 months

Text

Global Focus on Improved Outcomes: Global Neuro Immunoassay Market

The global neuro immunoassay market is poised for remarkable expansion, with projections indicating a surge to USD 5,303.1 million by 2033, according to recent market analysis. This forecast marks a substantial increase from its 2023 valuation of USD 2,616.1 million, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period.

Neuro immunoassay, a vital segment within the healthcare industry, plays a pivotal role in diagnosing and monitoring neurological disorders and autoimmune diseases. With advancements in technology and an evolving understanding of these conditions, the demand for accurate and efficient diagnostic tools is on the rise. Neuro immunoassay techniques offer a precise and reliable means of detecting biomarkers associated with various neurological and autoimmune conditions, driving their adoption across clinical settings worldwide.

Initiate In-Depth Research With Your Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-4293

The projected growth of the neuro immunoassay market underscores the increasing prevalence of neurological disorders and autoimmune diseases globally. As populations age and lifestyles evolve, the incidence of these conditions continues to escalate, necessitating advanced diagnostic solutions for timely intervention and management.

Key Takeaways:

The global neuro immunoassay market is expected to reach a value of US$5,303.1 million by 2033, reflecting a significant increase from US$2,616.1 million in 2023.

This growth is projected at a healthy compound annual growth rate (CAGR) of 7.3% during the forecast period.

The surge in demand is attributed to the crucial role of immunoassays in various applications like biopharmaceutical analysis, clinical diagnostics, and early disease detection.

Key Segments of the Neuro Immunoassay Market

By Technology:

Radioimmunoassays (RIA)

Polymerase Chain Reaction (PCR)

ELISA

Western Blot

Rapid Tests

ELISPOT

By Product Type:

Reagents and Kits

Analysers

By Application:

Alzheimer’s Disease

Parkinson’s Disease

Huntington’s Disease

Amyotrophic Lateral Sclerosis (ALS)

Spinal Muscular Atrophy (SMA)

By End User:

Hospitals

Clinics

Academic Organizations

Biopharmaceutical Companies

Pharmaceutical Companies

Others

By Region:

North America

Latin America

Asia Pacific

Middle East and Africa

Europe

#Neuro Immunoassay Market

0 notes

evoldir · 5 months

Text

Fwd: Graduate position: UMississippi.Treefrog.Polyploidization

Begin forwarded message: > From: [email protected] > Subject: Graduate position: UMississippi.Treefrog.Polyploidization > Date: 25 April 2024 at 06:27:21 BST > To: [email protected] > > > Ph.D. Position in Endocrinology of Polyploids. The Leary lab in the > Department of Biology (biology.olemiss.edu) at the University of > Mississippi is looking for a Ph.D. student with strong interests in > endocrinology. The candidate will be involved in a funded research project > aimed at understanding how polyploidization has impacted neuroendocrine > regulation in gray treefrogs. The candidate will learn mechanisms of > endocrine control, hormone manipulation procedures, radioimmunoassay, > and bioacoustics and will be directly involved in field data collection > from populations of frogs across the eastern United States. Background > in neuroendocrinology, radioimmunoassay procedures, or experience > working with amphibians is highly desirable but not required. Required > Qualifications: A strong interest in research involving amphibians and > endocrinology. Ability to work long hours in the field at night. This > position is for a term of up to three years as a research assistant > during the Spring and Summer and will be supplemented with departmental > teaching assistantships during the Fall semester. Please send inquiries > to Christopher Leary ([email protected]). Proposed Start Date: Fall > semester 2024 or sooner. > > > > Christopher J Leary

#IFTTT #Email

0 notes

twiainsurancegroup · 5 months

Link

0 notes

spookysaladchaos · 6 months

Text

Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent, Global Market Size Forecast, Top Ten Players Rank and Market Share

Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Summary

According to the new market research report "Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Report 2023-2029", published by QYResearch, the global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent market size is projected to grow from USD 253 Million in 2023 to USD 451 million by 2029, at a CAGR of 10.1% during the forecast period.

Figure. Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Size (US$ Million), 2018-2029

Based on or includes research from QYResearch: Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Report 2023-2029.

Market Drivers:

1. Increase in the number of diabetic patients: The prevalence of diabetes continues to increase globally. As the number of people with diabetes increases, so does the need for HbA1c testing to help patients manage their blood sugar levels.

2. Improvements in healthcare infrastructure: Healthcare infrastructure in some emerging markets and developing countries is improving, making diabetes testing and management available to more people. This will drive increased demand for HbA1c testing.

Restraint:

1. Competition between other methods and immunoturbidimetry: such as liquid chromatography, chemiluminescence, radioimmunoassay, etc.

2. Instrument matching: Reagents often need to be used with matching instruments, and reagent manufacturers often need to cooperate with instrument manufacturers to open the marke

Figure. Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Top Ten Players Ranking and Market Share（Continually updated）

Based on or includes research from QYResearch: Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Report 2023-2029.

Market Drivers:

1. Increase in the number of diabetic patients: The prevalence of diabetes continues to increase globally. As the number of people with diabetes increases, so does the need for HbA1c testing to help patients manage their blood sugar levels.

2. Improvements in healthcare infrastructure: Healthcare infrastructure in some emerging markets and developing countries is improving, making diabetes testing and management available to more people. This will drive increased demand for HbA1c testing.

Restraint:

1. Competition between other methods and immunoturbidimetry: such as liquid chromatography, chemiluminescence, radioimmunoassay, etc.

2. Instrument matching: Reagents often need to be used with matching instruments, and reagent manufacturers often need to cooperate with instrument manufacturers to open the marke

Figure. Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Top Ten Players Ranking and Market Share（Continually updated）

Based on or includes research from QYResearch: Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Report 2023-2029.

Market Drivers:

1. Increase in the number of diabetic patients: The prevalence of diabetes continues to increase globally. As the number of people with diabetes increases, so does the need for HbA1c testing to help patients manage their blood sugar levels.

2. Improvements in healthcare infrastructure: Healthcare infrastructure in some emerging markets and developing countries is improving, making diabetes testing and management available to more people. This will drive increased demand for HbA1c testing.

Restraint:

1. Competition between other methods and immunoturbidimetry: such as liquid chromatography, chemiluminescence, radioimmunoassay, etc.

2. Instrument matching: Reagents often need to be used with matching instruments, and reagent manufacturers often need to cooperate with instrument manufacturers to open the marke

Figure. Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Top Ten Players Ranking and Market Share（Continually updated）

Based on or includes research from QYResearch: Global Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent Market Report 2023-2029.

This report profiles key players of Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent such as DANAHER、Roche、Siemens Healthcare、Abbott、Mindray Medical、Beijing Strong Biotechnologies.

In 2022, the global top five Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent players account for 56% of market share in terms of revenue. Above figure shows the key players ranked by revenue in Glycated Hemoglobin Immunoturbidimetric Diagnostic Reagent.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

#report #research

0 notes

anxioushoneybadgers · 10 months

Text

Do you need a menstrual cycle to be affected by the moon? - Abby Maske

While one of our main focuses for our research in this page is the effect lunar events have on female menstrual cycles, we don't want to overlook men and the potential effects on them. For the other half of humans what occurs in their bodys and is it similar to women? We looked at a research study called “ Does the lunar cycle affect biological parameters in young healthy men?” by Chronobiology international. This study is the test of levels in youth men during a full moon and during a new moon. They used 24 healthy young men from 25 yrs old to 27 yrs old. During the test they showed no sleep disturbance according to the Pittsburgh sleep quality index. The blood tests they did were Radioimmunoassay kits (A68449 Melatonin RIA, IM1841 Cortisol RIA, and IM1087 Testosterone RIA, Beckman Coulter Laboratories, USA). The post hoc tests revealed that medical laboratory levels and TST(testosterone) levels were lower during the Full moon compared to the New moon, both in the morning. Although CRT (cortisol) levels were higher in the Full moon compared to the New moon, both in the morning. In the study summary it emphasizes “This is the ﬁrst study investigating the eﬀects of LC(lunar cycle) on diurnal variation of hormonal, biochemical, and hematolo-gical parameters in a light-controlled laboratory on healthy active men” This is necessary to our study to be able to cross compare with the statistics on womens bodys to get a better understanding of how our bodys as humans change with the lunar positioning. The main ﬁndings were that MLT, TST, and NEU levels were lower during the Full moon compared to the New moon both in the morning and evening. However, CRT levels were higher during the Full moon compared to the New moon both in the morning and evening. Interestingly, HB(heartbeat) levels were higher only on the evening of the Full moon compared to the New moon. The present study conﬁrms for the ﬁrst time that the Lunar cycle aﬀects the hormonal and hematological proﬁle of humans. “Whether moon phases modulate it is not evident and still needs to be explored.” This quote is why we have also taken the time to examine the effect on women as well during studies. The study proved that their levels of testosterone were slightly higher during a new moon but cortisol levels were lower during a new moon. The study confirmed that the stages of the moon create a biological event in the body’s blood. The study of the moon's effect on menstrual cycles meaning we focus on people presenting with menstrual cycles but not people without. This article allows for us to get insight on the possible changes that could be happening not only in body’s with menstrual cycles but also ones without. The test itself is a piece of evidence for our blog to be able to give facts to the physical effects of the lunar light on the body.

This graph shows the difference between the testosterone on a full moon vs. a new moon. P1 represents the cortisol levels in the subjects on a new moon whereas P2 represents the cortisol levels on the full moon. D1 represents the testosterone on a new moon whereras D2 represents the testosterone on a full moon.

The graph and essay are in referance to the work done by Dergaa I; Romdhani M;Fessi MS;Ben Saad H;Varma A;Ben Salem A;Gadhavi B;Chaabane M; Souissi N;Hammouda O; (2021, March 28). Does the lunar cycle affect biological parameters in young healthy men?. Chronobiology international.

1 note · View note

kenresearchreport · 11 months

Text

The Future of Esoteric Testing in the US: Growth, Technology, and Personalized Medicine

What is the Size of US Esoteric Testing Industry?

US Esoteric Testing Market is expected to grow at a CAGR of ~% between 2022-2028 and is expected to reach ~USD Mn by 2028.

Innovation and advancements in technology has open up new possibilities in esoteric markets. For instance, developments in manufacturing, materials science, or information technology have enabled the creation of novel and advanced products or services that appeal to a niche audience.

The rise of e-commerce and online platforms has made it easier for niche or esoteric products and services to reach a wider audience.

Us Esoteric Testing Market By Technology

The US Esoteric Testing market is segmented by technology into Chemiluminescence Immunoassay, Mass Spectrometry, RTPCR and Radioimmunoassay.

Based on technology, Chemiluminescence Immunoassay segment is emerged as the dominant segment US Esoteric Testing market in 2022.

Chemiluminescence Immunoassays offer a high level of sensitivity and specificity, making them particularly well-suited for detecting low concentrations of analytes, such as biomarkers, antigens, or antibodies, that are indicative of complex and rare medical conditions. This precision is crucial in esoteric testing where accurate and reliable results are paramount.

Us Esoteric Testing Market By Type

In US Esoteric Testing market, they are segmented by type into Infectious disease testing

Endocrinology, Oncology, Genetic and Toxicology.

Based On Type, Infectious disease emerged as the dominant segment in US Esoteric Testing market in 2022.

the continuous emergence of new and evolving infectious diseases, both within and outside of the pandemic context, has driven the development of advanced esoteric testing methodologies. The ability to rapidly detect, identify, and differentiate infectious agents is crucial for containing outbreaks and ensuring appropriate patient management.

Furthermore, the interconnectedness of the modern world through travel and trade has increased the risk of infectious disease outbreaks crossing borders. This has underscored the necessity for robust infectious disease testing capabilities.

Us Esoteric Testing By Region

The US Esoteric Testing market is segmented by Region into North, East, West and South.

In 2022, the dominance region is North region in US Esoteric Testing market. The North region, comprising states like New York, Massachusetts, and Illinois, houses a significant portion of the nation's leading healthcare and research institutions, creating a conducive environment for the growth of esoteric testing.

The North region is home to renowned medical centers, academic institutions, and research hubs, such as the Harvard Medical School, Massachusetts General Hospital, and Johns Hopkins University. These institutions foster a culture of innovation, cutting-edge research, and collaboration with diagnostic companies, leading to the development and adoption of advanced esoteric testing methodologies.

Download a Sample Report of US Esoteric Testing Future Market

Competition Scenario in US Esoteric Testing Market

The US esoteric testing market is characterized by intense competition among a diverse array of players, each striving to carve out a significant share in this rapidly evolving landscape. Major industry players include Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), ARUP Laboratories, Mayo Clinic Laboratories, and Sonic Healthcare, among others. These established diagnostic giants leverage their extensive network of laboratories, robust research capabilities, and longstanding expertise to dominate the market.

The competition in the US esoteric testing market is fueled by the race to develop new and more accurate tests, expand test portfolios, and establish strong relationships with healthcare providers. With the increasing emphasis on precision medicine and the utilization of genetic information for treatment decisions, the market's competitive landscape is likely to remain dynamic and vibrant, promoting continuous advancements in esoteric testing capabilities.

What is the Expected Future Outlook for the Overall US Esoteric Testing Market?

The US Esoteric Testing market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028.

The growing demand for personalized medicine is a major growth driver for the US esoteric testing market. As healthcare shifts towards tailored treatments, esoteric testing plays a important role in decoding an individual's genetic and physiological characteristics.

This allows healthcare providers to create personalized treatment plans, predict disease risks, and enhance medication effectiveness. The integration of esoteric testing into personalized medicine strategies drives its adoption, fuels demand for specialized diagnostics, and contributes to the market's expansion.

Esoteric testing, which involves complex and specialized diagnostic procedures aimed at identifying rare diseases or conditions, has gained significant attention due to its potential to uncover critical medical insights that conventional tests might miss.

The market's growth trajectory is expected to be fueled by advancements in technology, increasing awareness among healthcare professionals, and a growing demand for personalized medicine.

Furthermore, the US esoteric testing market is the rapid progress in medical technology. Innovations such as next-generation sequencing (NGS), mass spectrometry, and molecular diagnostics have enhanced the precision and accuracy of esoteric tests, making them more reliable for diagnosing intricate and elusive medical conditions. This technological evolution has expanded the scope of esoteric testing, enabling clinicians to identify genetic mutations, biomarkers, and metabolic abnormalities that play pivotal roles in disease onset and progression.

Furthermore, growing awareness among healthcare professionals about the potential benefits of esoteric testing is influencing its adoption. This heightened awareness is likely to lead to increased referrals for esoteric testing, propelling market expansion.

0 notes

chemicals1 · 1 year

Text

0 notes

autodaemonium · 1 year

Text

ɪdzraɪlærərisætdʃɪnpt

Pronounced: idzrailaruhrisatdshinpt.

Pantheon of: womanliness, affinity, speculativeness, incomprehensibility, disfigurement, judgment, artificiality.

Entities

Ndnnəðstfutnhtʃŋndktə

Pronounced: ndnnuhthstfutnhtshngndktuh Incomprehensibility: unintelligibility. Judgment: objectivity. Artificiality: staginess. Legends: committal service, kwanzaa. Prophecies: dawn, time. Relations: rflmdʌəzæɪətʃbtɪntaɪɪr (activated carbon), riewszŋwbnrlnmttwkeə (lard), ngədʒrvʊnniʃzkttaɪərən (medoc).

Ngədʒrvʊnniʃzkttaɪərən

Pronounced: nguhjrvoonnishzkttaiuhruhn Incomprehensibility: opacity. Judgment: subjectivity. Artificiality: staginess. Legends: measure, concession, combination, embezzlement, lead. Prophecies: regression, database management, self-assertion.

Rflmdʌəzæɪətʃbtɪntaɪɪr

Pronounced: rflmduuhzaiuhtshbtintaiir Incomprehensibility: inscrutability. Judgment: objectivity. Artificiality: pretension. Legends: lesson, blackening, insurgency, monolatry, nim. Prophecies: physiological nystagmus.

Riewszŋwbnrlnmttwkeə

Pronounced: riewszngwbnrlnmttwkeuh Incomprehensibility: obscureness. Judgment: subjectivity. Artificiality: staginess. Legends: shift, expulsion, passive resistance. Prophecies: cruise. Relations: rəɑŋʃrrɪivləɛdɪlzmrə (bond), rflmdʌəzæɪətʃbtɪntaɪɪr (time sharing).

Rəɑŋʃrrɪivləɛdɪlzmrə

Pronounced: ruhahngshrriivluhaydilzmruh Incomprehensibility: illegibility. Judgment: objectivity. Artificiality: staginess. Legends: bubble dance, rabbit punch, zap, radioimmunoassay, resignation. Prophecies: lullaby, killing, hecatomb, three-ring circus, trap block.

0 notes

healthcaremarketanalysis · 4 months

Text

Global Therapeutic Drug Monitoring Market worth $2.9 billion by 2027

Therapeutic Drug Monitoring Market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by the Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis. However, Alternatives to conventional TDM may challenge the growth of this market.

Attractive Opportunities in the Therapeutic Drug Monitoring Industry